Last reviewed · How we verify

Alprostadil ﹠control

Shanghai 10th People's Hospital · FDA-approved active Small molecule

Alprostadil is a prostaglandin E1 analog that vasodilates blood vessels and inhibits platelet aggregation.

Alprostadil is a prostaglandin E1 analog that vasodilates blood vessels and inhibits platelet aggregation. Used for Peripheral arterial occlusive disease, Intermittent claudication, Erectile dysfunction.

At a glance

Generic nameAlprostadil ﹠control
Also known asDrug: Alprostadil, lipo-alprostadil, Prostaglandin E1, Drug: normal salin
SponsorShanghai 10th People's Hospital
Drug classProstaglandin E1 analog
TargetProstanoid receptors (EP receptors)
ModalitySmall molecule
Therapeutic areaCardiovascular
PhaseFDA-approved

Mechanism of action

Alprostadil binds to prostanoid receptors on vascular smooth muscle and platelets, causing relaxation of vascular smooth muscle cells and increased blood flow. It also reduces platelet activation and aggregation, improving microcirculation and tissue perfusion. These effects make it useful in conditions characterized by poor blood flow and tissue ischemia.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: